Numis disclosed BTG PLC (LON:BTG), supporting its price target at 737.00GBX earlier today
- Updated: October 6, 2016
Having a price of 710.75GBX, BTG PLC (LON:BTG) traded 3.63% higher on the day. With the last stock price up 10.62% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. BTG has recorded a 50-day average of 627.97GBX and a two hundred day average of 640.80GBX. Trade Volume was down over the average, with 355,500 shares of BTG changing hands under the typical 588,749
Reporting a potential upside of 0.04%, Numis hold steady the price target of BTG PLC (LON:BTG) at 737.00GBX
On 10/6/2016, Stifel released a statement about BTG PLC (LON:BTG) maintained the target price at 640.00GBX that suggested a downside of -0.06%.
Recent Performance Chart
BTG PLC has 52 week low of 504.00GBX and a 52 week high of 739.50GBX with a P/E ratio of 45.44 and has a market cap of 0 GBX.
About BTG PLC (LON:BTG)
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.